Source link : https://www.newshealth.biz/health-news/nirsevimab-resistance-mutations-rare-in-rsv-study-shows/
Nirsevimab (Beyfortus), an antibody targeting respiratory syncytial virus (RSV), is indicated for newborns and infants to prevent bronchiolitis. Available since September 2023, its widespread use may lead to resistance mutations. However, according to the French POLYRES study on prospective monitoring of nirsevimab, published recently in The Lancet Infectious Diseases, these mutations are very rare at […]
Author : News Health
Publish date : 2024-11-15 11:20:26
Copyright for syndicated content belongs to the linked Source.